A Double-Blind, Placebo-Controlled, Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single/Multiple Ascending Doses of ATB-346 Orally Administered in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2017
Price : $35 *
At a glance
- Drugs ATB 346 (Primary)
- Indications Musculoskeletal pain; Pain
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Antibe Therapeutics
- 10 Aug 2015 Results published in Antibe Therapeutics media release.
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 17 Apr 2015 Additional validation data was published in an Antibe Therapeutics media release.